人肺腺癌ABCG2~+细胞的分选及其生物学特性研究
|
摘要
【目的】
本课题通过分析人肺腺癌细胞系经化疗药物作用后侧群(side population,SP)细胞的比例变化,以及利用免疫磁珠分选出耐药人肺腺癌细胞系中ABCG2+细胞并进行裸鼠移植瘤实验,初步探讨人肺腺癌干细胞样细胞的分选方法及其基本生物学特性。
【方法】
以小剂量阿霉素(Adriamycin,ADM)诱导人肺腺癌A549细胞系和SPC-A-1细胞系,比较亲代细胞和诱导后细胞的形态;绘制两系细胞诱导前后的增殖曲线,计算倍增时间;用MTT比色法检测多种化疗药物对肿瘤细胞增殖的杀伤效应;显微镜下测定诱导前后两系细胞中SP细胞比例。
以ADM诱导后的人肺腺癌SPC-A-1细胞系为研究对象,利用免疫磁珠分选出SPC-A-1/ADM细胞系中ABCG2+细胞和ABCG2-细胞,分别进行流式细胞分析及裸鼠体内移植,分析ABCG2+细胞和ABCG2-细胞的体内成瘤性。
【结果】
1.ADM诱导前后人肺腺癌细胞系的群体体外倍增时间和ADM诱导后人肺腺癌细胞系的耐药指数
ADM诱导前后A549细胞的群体体外倍增时间分别为37.6h和36.1h,并无显著差异(P=0.989,t=0.013)。A549/ADM细胞对ADM、顺铂、长春新碱、足叶乙甙、紫杉醇五种药物的耐药指数分别为9.588、6.348、1.736、11.213、4.333。ADM诱导前后SPC-A-1细胞的群体体外倍增时间分别为35.9h和35.6h,并无显著差异(P=0.956,t=0.056)。SPC-A-1/ADM细胞对ADM、顺铂、长春新碱、足叶乙甙、紫杉醇五种药物的耐药指数分别为4.283、3.672、6.308、9.112、2.716。
2.ADM诱导前后人肺腺癌细胞系中SP细胞比例变化
ADM诱导前后,A549细胞中SP细胞的比例分别为4%和45%,差别显著(X2=307.210,p=0.000);SPC-A-1细胞中SP细胞的比例分别为1%和10%,差别显著(X2=102.201,p=0.000)。
3.培养SPC-A-1和SPC-A-1/ADM细胞中ABCG2+细胞的比例变化
ABCG2染色荧光观察显示,在SPC-A-1/ADM细胞中,每个视野均可见被Mouse Anti-Human ABCG2/BCRP-FITC标记的细胞,ABCG2+细胞数量较SPC-A-1细胞中明显增多。
流式细胞分析结果显示,SPC-A-1细胞空白对照组中ABCG2+细胞比例为0.047% ,同型对照组中ABCG2 +细胞比例为0.087 % , Mouse Anti-Human ABCG2/BCRP-FITC标记的SPC-A-1细胞中ABCG2+细胞比例为0.247%,而Mouse Anti-Human ABCG2/BCRP-FITC标记的SPC-A-1/ADM细胞中ABCG2+细胞比例达到9.9%,是SPC-A-1细胞中ABCG2+细胞比例的40.08倍。
4.从SPC-A-1/ADM细胞中免疫磁珠分选ABCG2+细胞的得率及ABCG2+细胞的比例变化
结果显示,从SPC-A-1/ADM细胞中,每1×107个细胞可分离出2×104个ABCG2+细胞,ABCG2+细胞得率为0.2%。A群细胞中Mouse Anti-Human ABCG2/BCRP-FITC标记阳性率为0.127%,B群细胞中Mouse Anti-Human ABCG2/BCRP-FITC标记阳性率为84.71%,是A群细胞中Mouse Anti-Human ABCG2/BCRP-FITC标记阳性率的667t倍。
5.A群和B群人肺腺癌细胞的裸鼠体内成瘤能力比较
接种SPC-A-1细胞和A群细胞的裸鼠未见成瘤,成瘤率分别为0/4、0/4。接种B群细胞的裸鼠3周后开始成瘤,第8周时,共有3只裸鼠成瘤,成瘤率为3/4。
【结论】
1.人肺腺癌A549和SPC-A-1细胞系经过ADM诱导后对多种化疗药物的耐药性明显增加,耐药细胞中SP细胞的比例显著升高,提示SP细胞比例增加与肺腺癌的耐药性形成密切相关。
2.SPC-A-1/ADM细胞群中ABCG2表达阳性率显著高于SPC-A-1细胞,这为基于ABCG2来分离干细胞创造了条件。
3.SPC-A-1/ADM细胞群中的ABCG2+细胞裸鼠体内移植成瘤率较高,而ABCG2-细胞和SPC-A-1细胞在裸鼠体内未见移植瘤形成,表明基于ABCG2所分离的肺腺癌细胞具有干细胞特性。
Objective:The proportion of SP cells was analyzed in human lung adenocarcinoma cell lines induced by chemotherapeutic drug,and ABCG2+cells were isolated from multidrug resistant cell lines by magnetic activated cell sorting(MACS). Tumorigenicity was detected in nude mice. We studied primarily on the isolation method and biological characteristic of human lung adenocarcinoma stem-like cells.
Method:Human lung adenocarcinoma cell lines A549 and SPC-A-1 were induced by low dose adriamycin(ADM).The morphology of the cells was compared before and after induction.The growth curves in vitro were drew and their doubling times(DT) were calculated.The lethal effects were detected by MTT method and the proportion of the SP cells was assayed in the two cell lines under fluorescence microscope.
ABCG2+cells were isolated from drug resistance cell line SPC-A-1/ADM by MACS, and analyzed by flow cytometry.Then transplanted them into nude mice. The tumorigenicity of ABCG2+cells and ABCG2-cells was analyzed.
Result:
1. DT and resistance factor (RF) of human lung adenocarcinoma lines in vitro before and after induction by ADM.
The DT of A549 cell line in vitro before and after induction by ADM was 37.6h and 36.1h, respectively. The RF of A549/ADM cell line to ADM, DDP, VP-16, VCR, TAX was 9.588、6.348、1.736、11.213、4.333, respectively.
The DT of SPC-A-1 cell line in vitro before and after induction by ADM was 37.6h and 36.1h ,respectively. The RF of SPC-A-1/ADM cell line to ADM, DDP, VP-16, VCR, TAX was 4.283、3.672、6.308、9.112、2.716, respectively.
2. Proportion of SP cell in human lung adenocarcinoma cell line before and after induction by ADM.
The proportion of SP cell was 4% and 45% in A549 cell line before and after induction by ADM. The proportion of SP cell was 1% and 10% in SPC-A-1 cell line before and after induction by ADM.
3. Proportion of ABCG2+ cells in SPC-A-1 and SPC-A-1/ADM cells.
Under fluorescence microscope, cells labeled by Mouse Anti-Human ABCG2/BCRP-FITC were observed in each field of the SPC-A-1/ADM cells. The number of ABCG2+ cells in SPC-A-1/ADM cell line was more than SPC-A-1.
Flow cytometry analysis showed that the proportion of ABCG2+ cells in the blank group of SPC-A-1 cell line was 0.047%,in the isotype control group of SPC-A-1 cell line was 0.087%, in SPC-A-1/ADM cell line was 9.9%. It was 40.08 times higher than that of SPC-A-1cell line.
4. ABCG2+ cells isolated from SPC-A-1/ADM cell line by MACS.
Result revealed that 2×104 ABCG2 + cells could be isolated from 1×107 SPC-A-1/ADM cells. the separating proportion of the ABCG2+ cells was 0.2%. The positive rate of the cell labeled by Mouse Anti-Human ABCG2/BCRP-FITC in ABCG2- cells (group A) was 0.127%, the positive rate of the cell labeled by Mouse Anti-Human ABCG2/BCRP-FITC in ABCG2+ cells (group B) was 84.71% and it was 667 times higher than that of group A.
5. Tumorigenicity of group A and group B cells in nude mice.
The transplanted tumors were not found in SPC-A-1 cell group (0/4) and group A (0/4) at the 8th weekend. The transplanted tumors were found in group B at the 3 th weekend, at the 8th weekend, the tumorigenicity ratio was 3/4.
Conclusion:
1. The multidrug resistance increased obviously in A549 cell line and SPC-A-1cell line induced by ADM. The proportion of SP cell increased obviously in multidrug resistance cells. All of these implied that increasing of SP cells was related with multidrug resistance in human lung adenocarcinoma.
2. The proportion of ABCG2+ cells was higher in SPC-A-1/ADM cell line than that in SPC-A-1,and it would benefit for stem cell isolating base on SPC-A-1/ADM cells.
3. The tumorigenicity of ABCG2+ cells coming from SPC-A-1/ADM cell line was higher than that from ABCG2- cells and SPC-A-1 cells in nude mice. It indicated that the cells isolated from the chemotherapeutic drug resistant lung adenocacinoma based on ABCG2+ possess stem cell characteristics.
本课题通过分析人肺腺癌细胞系经化疗药物作用后侧群(side population,SP)细胞的比例变化,以及利用免疫磁珠分选出耐药人肺腺癌细胞系中ABCG2+细胞并进行裸鼠移植瘤实验,初步探讨人肺腺癌干细胞样细胞的分选方法及其基本生物学特性。
【方法】
以小剂量阿霉素(Adriamycin,ADM)诱导人肺腺癌A549细胞系和SPC-A-1细胞系,比较亲代细胞和诱导后细胞的形态;绘制两系细胞诱导前后的增殖曲线,计算倍增时间;用MTT比色法检测多种化疗药物对肿瘤细胞增殖的杀伤效应;显微镜下测定诱导前后两系细胞中SP细胞比例。
以ADM诱导后的人肺腺癌SPC-A-1细胞系为研究对象,利用免疫磁珠分选出SPC-A-1/ADM细胞系中ABCG2+细胞和ABCG2-细胞,分别进行流式细胞分析及裸鼠体内移植,分析ABCG2+细胞和ABCG2-细胞的体内成瘤性。
【结果】
1.ADM诱导前后人肺腺癌细胞系的群体体外倍增时间和ADM诱导后人肺腺癌细胞系的耐药指数
ADM诱导前后A549细胞的群体体外倍增时间分别为37.6h和36.1h,并无显著差异(P=0.989,t=0.013)。A549/ADM细胞对ADM、顺铂、长春新碱、足叶乙甙、紫杉醇五种药物的耐药指数分别为9.588、6.348、1.736、11.213、4.333。ADM诱导前后SPC-A-1细胞的群体体外倍增时间分别为35.9h和35.6h,并无显著差异(P=0.956,t=0.056)。SPC-A-1/ADM细胞对ADM、顺铂、长春新碱、足叶乙甙、紫杉醇五种药物的耐药指数分别为4.283、3.672、6.308、9.112、2.716。
2.ADM诱导前后人肺腺癌细胞系中SP细胞比例变化
ADM诱导前后,A549细胞中SP细胞的比例分别为4%和45%,差别显著(X2=307.210,p=0.000);SPC-A-1细胞中SP细胞的比例分别为1%和10%,差别显著(X2=102.201,p=0.000)。
3.培养SPC-A-1和SPC-A-1/ADM细胞中ABCG2+细胞的比例变化
ABCG2染色荧光观察显示,在SPC-A-1/ADM细胞中,每个视野均可见被Mouse Anti-Human ABCG2/BCRP-FITC标记的细胞,ABCG2+细胞数量较SPC-A-1细胞中明显增多。
流式细胞分析结果显示,SPC-A-1细胞空白对照组中ABCG2+细胞比例为0.047% ,同型对照组中ABCG2 +细胞比例为0.087 % , Mouse Anti-Human ABCG2/BCRP-FITC标记的SPC-A-1细胞中ABCG2+细胞比例为0.247%,而Mouse Anti-Human ABCG2/BCRP-FITC标记的SPC-A-1/ADM细胞中ABCG2+细胞比例达到9.9%,是SPC-A-1细胞中ABCG2+细胞比例的40.08倍。
4.从SPC-A-1/ADM细胞中免疫磁珠分选ABCG2+细胞的得率及ABCG2+细胞的比例变化
结果显示,从SPC-A-1/ADM细胞中,每1×107个细胞可分离出2×104个ABCG2+细胞,ABCG2+细胞得率为0.2%。A群细胞中Mouse Anti-Human ABCG2/BCRP-FITC标记阳性率为0.127%,B群细胞中Mouse Anti-Human ABCG2/BCRP-FITC标记阳性率为84.71%,是A群细胞中Mouse Anti-Human ABCG2/BCRP-FITC标记阳性率的667t倍。
5.A群和B群人肺腺癌细胞的裸鼠体内成瘤能力比较
接种SPC-A-1细胞和A群细胞的裸鼠未见成瘤,成瘤率分别为0/4、0/4。接种B群细胞的裸鼠3周后开始成瘤,第8周时,共有3只裸鼠成瘤,成瘤率为3/4。
【结论】
1.人肺腺癌A549和SPC-A-1细胞系经过ADM诱导后对多种化疗药物的耐药性明显增加,耐药细胞中SP细胞的比例显著升高,提示SP细胞比例增加与肺腺癌的耐药性形成密切相关。
2.SPC-A-1/ADM细胞群中ABCG2表达阳性率显著高于SPC-A-1细胞,这为基于ABCG2来分离干细胞创造了条件。
3.SPC-A-1/ADM细胞群中的ABCG2+细胞裸鼠体内移植成瘤率较高,而ABCG2-细胞和SPC-A-1细胞在裸鼠体内未见移植瘤形成,表明基于ABCG2所分离的肺腺癌细胞具有干细胞特性。
Objective:The proportion of SP cells was analyzed in human lung adenocarcinoma cell lines induced by chemotherapeutic drug,and ABCG2+cells were isolated from multidrug resistant cell lines by magnetic activated cell sorting(MACS). Tumorigenicity was detected in nude mice. We studied primarily on the isolation method and biological characteristic of human lung adenocarcinoma stem-like cells.
Method:Human lung adenocarcinoma cell lines A549 and SPC-A-1 were induced by low dose adriamycin(ADM).The morphology of the cells was compared before and after induction.The growth curves in vitro were drew and their doubling times(DT) were calculated.The lethal effects were detected by MTT method and the proportion of the SP cells was assayed in the two cell lines under fluorescence microscope.
ABCG2+cells were isolated from drug resistance cell line SPC-A-1/ADM by MACS, and analyzed by flow cytometry.Then transplanted them into nude mice. The tumorigenicity of ABCG2+cells and ABCG2-cells was analyzed.
Result:
1. DT and resistance factor (RF) of human lung adenocarcinoma lines in vitro before and after induction by ADM.
The DT of A549 cell line in vitro before and after induction by ADM was 37.6h and 36.1h, respectively. The RF of A549/ADM cell line to ADM, DDP, VP-16, VCR, TAX was 9.588、6.348、1.736、11.213、4.333, respectively.
The DT of SPC-A-1 cell line in vitro before and after induction by ADM was 37.6h and 36.1h ,respectively. The RF of SPC-A-1/ADM cell line to ADM, DDP, VP-16, VCR, TAX was 4.283、3.672、6.308、9.112、2.716, respectively.
2. Proportion of SP cell in human lung adenocarcinoma cell line before and after induction by ADM.
The proportion of SP cell was 4% and 45% in A549 cell line before and after induction by ADM. The proportion of SP cell was 1% and 10% in SPC-A-1 cell line before and after induction by ADM.
3. Proportion of ABCG2+ cells in SPC-A-1 and SPC-A-1/ADM cells.
Under fluorescence microscope, cells labeled by Mouse Anti-Human ABCG2/BCRP-FITC were observed in each field of the SPC-A-1/ADM cells. The number of ABCG2+ cells in SPC-A-1/ADM cell line was more than SPC-A-1.
Flow cytometry analysis showed that the proportion of ABCG2+ cells in the blank group of SPC-A-1 cell line was 0.047%,in the isotype control group of SPC-A-1 cell line was 0.087%, in SPC-A-1/ADM cell line was 9.9%. It was 40.08 times higher than that of SPC-A-1cell line.
4. ABCG2+ cells isolated from SPC-A-1/ADM cell line by MACS.
Result revealed that 2×104 ABCG2 + cells could be isolated from 1×107 SPC-A-1/ADM cells. the separating proportion of the ABCG2+ cells was 0.2%. The positive rate of the cell labeled by Mouse Anti-Human ABCG2/BCRP-FITC in ABCG2- cells (group A) was 0.127%, the positive rate of the cell labeled by Mouse Anti-Human ABCG2/BCRP-FITC in ABCG2+ cells (group B) was 84.71% and it was 667 times higher than that of group A.
5. Tumorigenicity of group A and group B cells in nude mice.
The transplanted tumors were not found in SPC-A-1 cell group (0/4) and group A (0/4) at the 8th weekend. The transplanted tumors were found in group B at the 3 th weekend, at the 8th weekend, the tumorigenicity ratio was 3/4.
Conclusion:
1. The multidrug resistance increased obviously in A549 cell line and SPC-A-1cell line induced by ADM. The proportion of SP cell increased obviously in multidrug resistance cells. All of these implied that increasing of SP cells was related with multidrug resistance in human lung adenocarcinoma.
2. The proportion of ABCG2+ cells was higher in SPC-A-1/ADM cell line than that in SPC-A-1,and it would benefit for stem cell isolating base on SPC-A-1/ADM cells.
3. The tumorigenicity of ABCG2+ cells coming from SPC-A-1/ADM cell line was higher than that from ABCG2- cells and SPC-A-1 cells in nude mice. It indicated that the cells isolated from the chemotherapeutic drug resistant lung adenocacinoma based on ABCG2+ possess stem cell characteristics.
引文
1. Hewitt H B. Studies of the dissemination and quantitative transplantation of a lymphocytic leukemia of CBA inice[J]. Br J Cancer 1958, 12(3):378-401
2. Reya T, Morrison S J, Clarke M F, Weissman I L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859) : 105 - 111.
3. Lapidot T,Sirard C,Vormoor J,Murdoch B, Hoang T, Caceres Cortes J, Minden M, Paterson B, Caligiuri M A, Dick J E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J].Nature,1994,367(6464):645-648.
4. Clarke M F,Morrison S J,Wicha M S. Isolation and use of solid tumor stem cells [M]. United States Patent Application, 2002, 20020119565.
5. Michael F, Clarke M F, John E, et al. Cancer Stem Cells - Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells[J]. Cancer Res, 2006, 66: 9339 - 9344.
6. Dick J E. Breast cancer stem cells revealed[J]. Proc Natl Acad Sci U S A,2003, 100 (7) : 3547-3549.
7. Potten C S,Hume W J,Reid P,Cairns J. The segregarion of DNA in epithelial stem cells[J]. Cell, 1978,15(3):899-906.
8. Goodell M A, Brose K, Paradis G, Conner A S, Mulligan R C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo[J]. J Exp Med, 1996, 183 (4): 1797 - 1806.
9. Zhou S, Morris J J, Barnes Y, Lan L, Schuetz J D, Sorrentino B F. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J].Proc Natl Acad Sci U S A, 2002, 99(19):12339- 12344.
10.吴一龙主编.非小细胞肺癌的多学科综合治疗策略[M].北京:人民卫生出版社,2000:178-229.
11. Dean M,Fojo T,Bates S. Tumour stem cells and drug resistance[J]. Nat Rev Cancer,2005,5(4):275-284.
12.司徒镇强,吴军正主编.细胞培养[M].西安:世界图书出版西安分公司,2007.1:200-201.
13. Hamburger A W, Salmon S E. Primary bioassay of human tumor stem cells[J]. Science, 1977, 197(4302): 461～463.
14. Al Hajj M, Wicha M S, Benito Hernandez A, Morrison S J, Clarke M F. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA , 2003 ,100 (7) : 3983-3988.
15. Tang D G, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider Broussard R, Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications[J]. Mol Carcinog, 2007, 46(1):1-14.
16. Saffran D C, Raitano A B, Hubert R S, Witte O N, Reiter R E, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts[J]. Proc Natl Acad Sci USA,2001,98 (5):2658-2663.
17. Reya T, Morrison S J, Clarke M F, Weissman I L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859): 105 - 111.
18. Gussoni E, Soneoka Y, Strickland C D, Buzney E A, Khan M K, Flint A F, Kunkel L M, Mulligan R C. Dystrophin expression in the mdx mouse restored by stem cell transplantation[J]. Nature, 1999, 401(6751): 390～394.
19.谢超,裴雪涛. ABCG2/Bcrp1转运蛋白:侧群干细胞的表型标记与功能调控蛋白.生理科学进展,2003,34(1):57-59.
20. Falciatori I, Borsellino G, Haliassos N, Boitani C, Corallini S, Battistini L, Bernardi G, Stefanini M, Vicini E. Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis[J]. FASEB J, 2004,18(2):376- 388.
21. Chiba T, Kita K, Zheng Y W, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side Population Purified From Hepatocellular Carcinoma Cells Harbors Cancer Stem Cell-like Properties[J]. Hepatology, 2006, 44(1):240-251.
22. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem like cells in the C6 glioma cell line[J] . Proc Natl Acad Sci USA, 2004,101 (3): 781 - 786.
23. Zhou S, Schuetz J D, Bunting K D, Colapietro A M, Sampath J, Morris J J, Lagutina I, Grosveld G C, Osawa M, Nakauchi H, Sorrentino B P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a moleculardeterminant of the side population phenotype[J]. Nat Med, 2001,7(9): 1028- 1034.
24. Schinkel A H, Mayer U, Wagenaar E, Mol C A, van Deemter L, Smit J J, van-der-Valk M A, Voordouw A C, Spits H, van-Tellingen O, Zijlmans J M, Fibbe W E, Borst P. Normal viability and altered Pharmacokinetics in mice Lacking mdr1- type (drug- transporting) P-glycoproteins[J]. Proc Natl Acad Sci U S A, 1997, 94(8): 4028- 4033.
25. Zhou S, Morris J J, Barnes Y, Lan L, Schuetz J D, Sorrentino B F. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J]. Proc Natl Acad Sci USA,2002,99(19): 12339- 12344.
26. Bunting K D, Zhou S, Lu T, Sorrentino B P. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo[J]. Blood,2000,96(3): 902-909.
27. Geschwind D H, Ou J, Easterday M C, Dougherty J D, Jackson R L, Chen Z, Antoine H, Terskikh A, Weissman I L, Nelson S F, Kornblum H I. A genetic analysis of neural progenitor differentiation[J]. Neuron , 2001 ,29(2):325～339.
28. Terskikh A V, Easterday M C, Li L, Hood L, Kornblum H I, Geschwind D H, Weissman I L. From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs[J]. Proc Natl Acad Sci USA , 2001, 98(14):7034-7939.
29. Chen Y N, Mickley L A, Schwartz A M, Acton E M, Hwang J L, Fojo A T. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein[J].J Biol Chem, 1990, 265(17): 10073-10080.
30. Doyle L A, Yang W ,Abruzzo L V, Krogmann T, Gao Y, Rishi A K, Ross D D. A multidrug resistance transporter from Human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci USA, 1998, 95(26): 15665-15670.
31. Krishnamurthy P, Schuetz J D. Role of ABCG2/BCRP in biology and medicine[J]. Annu Rev Pharmacol Toxicol, 2006,46:381-410.
32. Zhang W, Mojsilovic-Petrovic J, Andrade M F, Zhang H, Ball M, Stanimirovic D B. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels[J]. FASEB J, 2003, 17(14):2085 - 2087.
33. Robey R W, Honjo Y,Morisaki K, Nadjem T A, Runge S, Risbood M, Poruchynsky MS, Bates S E. Mutations at amin-oacid 482 in the ABCG2 gene affect substrate and antagonist specificity[J]. Br J Cancer, 2003,89(10):1971 - 1978.
34. Naylor C S, Jaworska E, Branson K, Embleton M J, Chopra R. Side population/ABCG2-positive cells represent a heterogeneous group of haemopoietic cells: Implications for the use of adult stem cells in transplantation and plasticity protocols[J]. Bone Marrow Transplant, 2005,35(4):353- 360.
35. Lechner A, Leech C A, Abraham E J, Nolan A L, Habeler J F. Nestin positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter [J]. Biochem Biophys Res Commun, 2002, 293: 670 - 674.
36. Wulf G G, Luo K L, Jackson K A, Brenner M K, Goodell M A. Cells of the hepaticside population contribute to liver regeneration and can be replenished with bone marrow stem cells[J]. Haematologica, 2003, 88(4):368- 378.
37. Summer R, Kotton D N, Sun X, Ma B, Fitzsimmons K, Fine A. Side population cells and Bcrp1 expression in lung[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 285(1):L97- 104.
1. SELL S. Stem cell origin of cancer and differentiation therapy [J]. Crit Rev Oncol Hematol,2004,51(1):1-28.
2. Hewitt H B.Studies of the dissemination and quantitative transplantation of alymphocytic leukemia of CBA in mice [J]. Br J Cancer 1958,12(3):378-401
3. Lapidot T,Sirard C,Vormoor J,Murdoch B,Hoang T,Caceres Cortes J,Minden M,Paterson B,Caligiuri M A,Dick J E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J].Nature,1994,367(6464):645-648.
4. Reya T, Morrison S J, Clarke M F, Weissman I L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859): 105 - 111.
5. Clarke M F,Morrison S J,Wicha M S. Isolation and use of solid tumor stem cells [M]. United States Patent Application, 2002, 20020119565.
6. Michael F, Clarke M F, John E. Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells[J]. Cancer Res, 2006, 66: 9339 - 9344.
7. Dick J E. Breast cancer stem cells revealed[J]. Proc Natl Acad Sci USA,2003, 100 (7) : 3547-3549.
8. Fialkow P J.Clonal origin of human tumors[J].Biochim Biophys Acta,1976,458 (3):283-321.
9. Pathak S. Organ- and tissue-specific stem cells and carcinogenesis[J].Anticancer Res,2002,22(3):1353-1356.
10. Keith W N. From stem cells to cancer: balancing immortality and neoplasia[J]. Oncogene, 2004, 23(29): 5092 - 5094.
11. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells[J]. Nature, 2003, 423 (6937): 255 -260.
12. Tsai RY. A molecular view of stem cell and cancer cell self - renewal[J]. Int J Biochem Cell Biol,2004, 36 (4): 684 - 694.
13. Lee J H,Schutte D,Wulf G,Fuzesi L,Radzun H J,Schweyer S,Engel W,Nayernia K. Stem cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl·XL pathway[J]. Hum Mol Genet, 2006, 15 (2): 201 - 211.
14. Krtolica A. Stem cell: balancing aging and cancer[J]. Int J Biochem Cell Biol, 2005, 37 (5): 935-941.
15. Yuspa S H,Morgan D L. Mouse skin cells resistant to terminal differentiation associated with initiation of carcinogenesis[J].Nature,1981,293(5827):72-74.
16. Bonnet D, Dick J E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med,1997, 3 (7) : 730 - 737.
17. Al Hajj M,Wicha M S,Benito Hemandez A,Morrison S J,Clarke M F.Prospective identification of tumorigenic breast cancer cells[J].Proc Natl Acad Sci USA,2003,100(7):3983-3988.
18. Sell S,Pierce G B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers[J].Lab Invest,1994,70(1):6-22.
19. Renan M J.How many mutations are required for tumorigenesis?Implications from human cancer data[J].Mol Carcinog,1993,7(3):139-146.
20. Potten C S,Hume W J,Reid P,Cairns J.The segregation of DNA in epithelial stem cells[J].Cell,1978,15(3):899-906.
21. Trosko J E,Chang C C.Stem cell of carcinogenesis[J].Toxicol Lett,1989,49 (2-3):283-295.
22. Li L, Neaves W B. Normal Stem Cells and Cancer Stem Cells: the niche matters[J]. Cancer Res,2006,66 (9): 4553 - 4557.
23. Yuan Y,Zhou L,Miyamoto T,Iwasaki H,Harakawa N,Hetherington C J,Burel S A,Lagasse E,Weissman I L,Akashi K,Zhang D E. AML1 - ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations [J]. Proc Natl Acad Sci USA,2001, 98 (18): 10398 - 10403.
24. Jamieson C H, Ailles L E, Dylla S J,Muijtjens M,Jones C,Zehnder J L,Gotlib J,Li K,Manz M G,Keating A,Sawyers C L,Weissman I L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML[J].N Engl J Med,2004,351(7): 657-667.
25. Kuo Y H,Landrette S F, Heilman S A, Perrat P N, Garrett L, Liu P P, Le Beau M M, Kogan S C, Castilla L H. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia[J]. Cancer Cell,2006, 9 (1): 57-68.
26. Blair A,Hogge D E,Sutherland H J.Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(+)/HLA-DR(-)[J]. Blood, 1998, 92(11):4325-4335.
27. Blair A, Hogge D E, Ailles L E, Lansdorp P M, Sutherland H J. Lack of expression of Thy-1 ( CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo[J ]. Blood,1997,89 (9) :3104-3112.
28. Blair A,Sutherland H J. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117) [J]. Exp Hematol,2000 ,28 (6):660-671.
29. Jordan C T, Upchurch D, Szilvassy S J, Guzman M L, Howard D S, Pettigrew A L, Meyerrose T, Rossi R, Grimes B, Rizzieri D A, Luger S M, Phillips G L. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells[J] .Leukemia,2000,14(10):1777-1784.
30. Guzman M L, Neering S J, Upchurch D, Grimes B, Howard D S, Rizzieri D A, Luger S M, Jordan C T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood, 2001,98 ( 8 ):2301-2307.
31. Guzman M L, Swiderski C F, Howard D S, Grimes B A, Rossi R M, Szilvassy S J, Jordan C T. Preferential induction of apoptosis for primary human leukemic stem cells[J ]. Proc Natl Acad Sci USA,2002, 99 (25):16220-16225.
32. Wang J C, Dick J E. Cancer stem cells: Lessons from leukemia[J]. Trends Cell Biol, 2005,15 (9): 494-501.
33. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti M A, Daidone M G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem /progenitor cell properties[J]. Cancer Res, 2005, 65(13): 5506-5511.
34. Ignatova T N, Kukekov V G, Laywell E D,Suslov O N,Vrionis F D, Steindler D A. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro[J]. Glia,2002,39(3):193-206.
35. Singh S K, Clarke I D, Terasaki M, Bonn V E, Hawkins C, Squire J, Dirks P B. Identification of a cancer stem cell in human brain tumors[J].Cancer Res, 2003,63(18):5821-5828.
36. Singh S K,Hawkins C, Clarke I D, Squire J A, Bayani J, Hide T, Henkelman R M,Cusimano M D,Dirks P B.Identification of human brain tumour initiating cells[J]. Nature,2004,432(7015):396-401.
37. Fomchenko E I,Holland E C.Stem cells and brain cancer[J].Exp Cell Res,2005,306(2): 323-329.
38. Hemmati H D, Nakano I, Lazareff J A, Masterman Smith M, Geschwind D H, Bronner Fraser M, Kornblum H I. Cancerous stem cells can arise f rom pediatric brain tumors [J] . Proc Natl Acad Sci USA, 2003,100 (25): 15178-15183.
39. Richardson G D, Robson C N, Lang S H, Neal D E, Maitland N J, Collins A T. CD133,a novel marker for human prostatic epithelial stem cells[J].J Cell Sci, 2004,117(16): 3539 - 3545.
40. Liu A Y,True L D,LaTray L,Ellis W J,Vessella R L,Lange P H,Higano C S,Hood L,van den Engh G. Analysis and sorting of prostate cancer cell types by flow cytometry[J]. Prostate,1999,40(3):192 - 199.
41. Collins A T, Berry P A, Hyde C, Stower M J, Maitland N J. Prospective identification of tumorigenic prostate cancer stem cells[J]. Cancer Res, 2005, 65(23)∶10946-10951.
42. Li C, Heidt D G, Dalerba P,Burant C F,Zhang L,Adsay V,Wicha M,Clarke M F,Simeone D M. Identification of pancreatic cancer stem cells[J]. Cancer Res, 2007, 67 (3):1030 -1037.
43. Seigel G M, Campbell L M,Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma[J]. Mol Vis,2005,11: 729 - 737.
44. Kim C F, Jackson E L, Woolfenden A E, Lawrence S, Babar I, Vogel S, Crowley D, Bronson R T, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer [J].Cell, 2005, 121 (6):823 - 835.
45. Fang D, Nguyen T K, Leishear K, Finko R, Kulp A N, Hotz S, Van Belle P A, Xu X, Elder D E, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas [J]. Cancer Res, 2005, 65 (20):9328 - 9337.
46. Gomella L G, Sargent E R, Wade T P, Anglard P, Linehan W M, Kasid A. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma [J]. Cancer Res, 1989, 49 (24 Pt 1): 6972-6975.
47. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus M C, Cantino D, Camussi G. Isolation of renal progenitor cells f rom adult human kidney [J]. Am J Pathol,2005,166 (2)∶545-555.
48. Forbes S, Vig P,Poulsom R,Thomas H, Alison M. Hepatic stem cells[J]. J Pathol, 2002,197(4):510-518.
49. Parent R, Marion M J, Furio L, Trepo C, Petit M A. Origin and characterization of a human bipotent liver progenitor cell line[J].Gastroenterology,2004,126(4): 1147-1156.
50. Hixson D C,Chapman L,McBride A,Faris R, Yang L.Antigenic phenotypes common to rat oval cells,primary hepatocellular carcinomas and developing bile ducts[J]. Carcinogenesis,1997,18(6):1169-1175.
51. Houghton J M, Stoicov C, Nomura S, Rogers A B, Carlson J, Li H, Cai X, Fox J G, Goldenring J R, Wang T C. Gastric cancer originating from bone Marrow-derived Cells [J]. Science,2004,306( 5701): 1568-1571.
52. O’Brien C A, Pollett A, Gallinger S,Dick J E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice [J]. Nature, 2007, 445 (7123): 106 - 110.
53. Ping Zhang,Hui Zuo,Takashi Ozaki,Nami Nakagomi,Kennichi Kakudo. Cancer stem cell hypothesis in thyroid cancer[J]. Pathology International, 2006, 56: 485 - 489.
54. Chan K S, Ailles L. Identification and characterization of cancer stem cells in bladder cancer[J]. Journal of Urology,2007, 177 (4): 257 - 257.
55. Goodell M A, Rosenzweig M, Kim H, Marks D F, DeMaria M, Paradis G, Grupp S A, Sieff C A, Mulligan R C, Johnson R P. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species[J]. Nat Med,1997,3(12):1337- 1345.
56. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in t he C6 glioma cell line[J]. Proc Natl Acad Sci USA, 2004,101 (3): 781 - 786.
57. Schinkel A H, Mayer U, Wagenaar E, Mol C A, van-Deemter L, Smit J J, van-der-Valk M A, Voordouw A C, Spits H, van-Tellingen O, Zi jlmans J M, Fibbe W E, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug- transporting) P- glycoproteins[J]. Proc Natl Acad Sci USA,1997,94(8): 4028- 4033.
58. Zhou S, Morris J J, Barnes Y, Lan L, Schuetz J D, Sorrentino B F. Bcrp1 geneexpression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J]. Proc Natl Acad Sci USA,2002,99(19):12339- 12344.
59. Zhou S, Schuetz J D, Bunting K D, Colapietro A M, Sampath J, Morris J J, Lagutina I, Grosveld G G, Osawa M, Nakauchi H, Sorrentino B P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype [J]. Nat Med, 2001, 7(9): 1028 - 1034.
60. Gussoni E, Soneoka Y,Strickland C D,Buzney E A,Khan M K,Flint A F,Kunkel L M,Mulligan R C. Dystrophin expression in the mdx mouse restored by stem cell transplantation[J]. Nature,1999, 401(6751):390- 394.
61. Falciatori I, Borsellino G, Haliassos N, Boitani C, Corallini S, Battistini L, Bernardi G, Stefanini M, Vicini E. Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis[J].FASEB J,2004,18(2): 376- 378.
1. Janes S M,Lowell S, Hutter C. Epidermal stem cells[J]. J Pathol, 2002,197(4): 479-491.
2. Lagasse E, Shizuru J A, Uchida N, Tsukamoto A, Weissman I L. Toward regenerative medicine[J]. Immunity,2001,14(4):425-436.
3. Perl A K,Wert S E,Nagy A,Lobe C G, Whitsett J A. Early restriction of peripheral and proximal cell lineages during formation of the lung[J]. Proc Natl Acad Sci USA,2002,99(16): 10482-10487.
4. Inayama Y, Hook G E, Brody AR, Jetten A M, Gray T, Mahler J, Nettesheim P. In vitro and in vivo growth and differentiation of clones of tracheal basal cells[J]. Am J Pathol,1989,134(3):539-549.
5. Ford J R, Terzaghi Howe M. Basal cells are the progenitors of primary tracheal epithelial cell cultures[J]. Exp Cell Res, 1992,198(1): 69-77.
6. Hong K U, Reynolds S D, Watkins S, Fuchs E, Stripp B R.In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent sub -populations[J]. Am J Physiol Lung Cell Mol Physiol,2004,286(4): L643-L649.
7. Borthwick D W, Shahbazian M, Krantz Q T,Dorin J R,Randell S H. Evidence for stem-cell niches in the tracheal epithelium[J].Am J Respir Cell Mol Biol,2001,24(6): 662-670.
8. Park K S, Wells J M,Zorn A M,Wer S E,Laubach V E,Fernandez L G,Whitsett J A. Transdifferentiation of ciliated cells during repair of the respiratory epithelium[J]. Am J Respir Cell Mol Biol, 2006,34(2): 151-157.
9. Reynolds S D, Giangreco A, Power J H, Stripp B R. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration[J]. Am J Pathol,2000,156 (1): 269-278.
10. Kim C F,J ackson E L,Woolfenden A E,Lawrence S,Babar I,Vogel S,Crowley D,Bronson R T,Jacks T.Identification of bronchioalveolar stem cells innormal lung and lung cancer[J]. Cell,2005,121(6): 823-835.
11. Kapanci Y, Weibel E R, Kaplan H P, Robinson F R. Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys.II Ultrastructural andmorphometric studies[J]. Lab Invest,1969,20(1): 101-118.
12. Evans M J,Cabral L J,Stephens R J,Freeman G. Renewal of alveolar epithelium in the rat following exposure to NO2[J]. Am J Pathol, 1973,70(2): 175-198.
13. Reddy R, Buckley S,Doerken M, Barsky L, Weinberg K,Anderson K D, Warburton D, Driscoll B. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells[J]. Am J Physiol Lung Cell Mol Physiol,2004,286(4): L658-L667.
14. Danto S I, Zabski S M, Crandall ED. Reactivity of alveolar epithelial cells in primary culture with type I cell monoclonal antibodies[J]. Am J Respir Cell Mol Biol,1992,6(3): 296-306.
15. Minguell J J,Erices A,Conget P.Mesenchymal stem cells[J]. Exp Biol Med,2001,226(12): 507-520.
16. Bruder S P,Jaiswal N, Haynesworth S E. Growth kinetics, self-renewal, and the osteogential potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation[J]. J Cell Biochem,1997, 64(2):278-294.
17. Prockop D J. Marrow stromal cells as stem cells for nonhematopoietic tissues[J]. Science,1997,276(5309): 71-74.
18. Krause D C,Theise N D,Collector M I,Henegariu O,Hwang S,Gardner R,Neutzel S,Sharkis S J. Multi-organ,multi-lineage engraftment by a single bone marrow-derived stem cell[J].Cell,2001,105(3): 369-377.
19. Albera C,Polak J M,Janes S,Griffiths M J,Alison M R,Wright N A,Navaratnarasah S,Poulsom R,Jeffery R,Fisher C,Burke M,Bishop A E. Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair[J]. Tissue Eng,2005,11(7-8) :1115-1121.
20. Kleeberger W, Versmold A, Rothamel T, Glockner S, Bredt M, Haverich A, Lehmann U,Kreipe H.Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury[J]. American Journal of Pathology,2003,162(5) : 1487-1494.
21. Sell S. Stem cell origin of cancer and differentiation therapy[J]. Crit Rev Oncol Hematol,2004,51 (1):1-28.
22. Burkert J,Wright N A,Alsion M R. Stem cells and cancer: an intimate relationship[J] . J Pathol,2006, 209 (3): 287 - 297.
23. Reya T,Morrison S J,Clarke M F,Weissman I L. Stem cells,cancer,and cancer stem cells[J]. Nature,2001,414(6859): 105 - 111.
24. Van der Kooy D, Weiss S. Why stem cells? [J]. Science,2000,287 (5457): 1439 - 1441.
25. Slack J M W. Stem cell in epithelial tissues[J]. Science,2000,287 (5457): 1431 - 1433.
26. Behbod F,Rosen J M. Will cancer stem cells provide new therapeutic targets? [J]. Carcinogenesis,2005,26 (4):703-711.
27. Berns A. Stem cells for lung cancer? [J]. Cell,2005,121 (6): 811-813.
28.黄盛东,刘晓红,白辰光.A549肺癌细胞株中肿瘤干细胞与克隆形成的关系[J].中华实验外科杂志,2006,23(9):1053-1055.
29. Robev R W,Honjo Y,van de Laar A,Miyake K,Regis J T,Litman T,Bates S E. A functional assay for detection of the mitoxantrone resistance protein,MXR (ABCG2) [J]. Biochim Biophys Acta. 2001,1512(2):171-182.
30. Ho M M,Ng A V,Lam S,Hung J Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J]. Cancer Res.2007,67(10): 4827-4833.
2. Reya T, Morrison S J, Clarke M F, Weissman I L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859) : 105 - 111.
3. Lapidot T,Sirard C,Vormoor J,Murdoch B, Hoang T, Caceres Cortes J, Minden M, Paterson B, Caligiuri M A, Dick J E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J].Nature,1994,367(6464):645-648.
4. Clarke M F,Morrison S J,Wicha M S. Isolation and use of solid tumor stem cells [M]. United States Patent Application, 2002, 20020119565.
5. Michael F, Clarke M F, John E, et al. Cancer Stem Cells - Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells[J]. Cancer Res, 2006, 66: 9339 - 9344.
6. Dick J E. Breast cancer stem cells revealed[J]. Proc Natl Acad Sci U S A,2003, 100 (7) : 3547-3549.
7. Potten C S,Hume W J,Reid P,Cairns J. The segregarion of DNA in epithelial stem cells[J]. Cell, 1978,15(3):899-906.
8. Goodell M A, Brose K, Paradis G, Conner A S, Mulligan R C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo[J]. J Exp Med, 1996, 183 (4): 1797 - 1806.
9. Zhou S, Morris J J, Barnes Y, Lan L, Schuetz J D, Sorrentino B F. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J].Proc Natl Acad Sci U S A, 2002, 99(19):12339- 12344.
10.吴一龙主编.非小细胞肺癌的多学科综合治疗策略[M].北京:人民卫生出版社,2000:178-229.
11. Dean M,Fojo T,Bates S. Tumour stem cells and drug resistance[J]. Nat Rev Cancer,2005,5(4):275-284.
12.司徒镇强,吴军正主编.细胞培养[M].西安:世界图书出版西安分公司,2007.1:200-201.
13. Hamburger A W, Salmon S E. Primary bioassay of human tumor stem cells[J]. Science, 1977, 197(4302): 461～463.
14. Al Hajj M, Wicha M S, Benito Hernandez A, Morrison S J, Clarke M F. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA , 2003 ,100 (7) : 3983-3988.
15. Tang D G, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider Broussard R, Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications[J]. Mol Carcinog, 2007, 46(1):1-14.
16. Saffran D C, Raitano A B, Hubert R S, Witte O N, Reiter R E, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts[J]. Proc Natl Acad Sci USA,2001,98 (5):2658-2663.
17. Reya T, Morrison S J, Clarke M F, Weissman I L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859): 105 - 111.
18. Gussoni E, Soneoka Y, Strickland C D, Buzney E A, Khan M K, Flint A F, Kunkel L M, Mulligan R C. Dystrophin expression in the mdx mouse restored by stem cell transplantation[J]. Nature, 1999, 401(6751): 390～394.
19.谢超,裴雪涛. ABCG2/Bcrp1转运蛋白:侧群干细胞的表型标记与功能调控蛋白.生理科学进展,2003,34(1):57-59.
20. Falciatori I, Borsellino G, Haliassos N, Boitani C, Corallini S, Battistini L, Bernardi G, Stefanini M, Vicini E. Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis[J]. FASEB J, 2004,18(2):376- 388.
21. Chiba T, Kita K, Zheng Y W, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side Population Purified From Hepatocellular Carcinoma Cells Harbors Cancer Stem Cell-like Properties[J]. Hepatology, 2006, 44(1):240-251.
22. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem like cells in the C6 glioma cell line[J] . Proc Natl Acad Sci USA, 2004,101 (3): 781 - 786.
23. Zhou S, Schuetz J D, Bunting K D, Colapietro A M, Sampath J, Morris J J, Lagutina I, Grosveld G C, Osawa M, Nakauchi H, Sorrentino B P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a moleculardeterminant of the side population phenotype[J]. Nat Med, 2001,7(9): 1028- 1034.
24. Schinkel A H, Mayer U, Wagenaar E, Mol C A, van Deemter L, Smit J J, van-der-Valk M A, Voordouw A C, Spits H, van-Tellingen O, Zijlmans J M, Fibbe W E, Borst P. Normal viability and altered Pharmacokinetics in mice Lacking mdr1- type (drug- transporting) P-glycoproteins[J]. Proc Natl Acad Sci U S A, 1997, 94(8): 4028- 4033.
25. Zhou S, Morris J J, Barnes Y, Lan L, Schuetz J D, Sorrentino B F. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J]. Proc Natl Acad Sci USA,2002,99(19): 12339- 12344.
26. Bunting K D, Zhou S, Lu T, Sorrentino B P. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo[J]. Blood,2000,96(3): 902-909.
27. Geschwind D H, Ou J, Easterday M C, Dougherty J D, Jackson R L, Chen Z, Antoine H, Terskikh A, Weissman I L, Nelson S F, Kornblum H I. A genetic analysis of neural progenitor differentiation[J]. Neuron , 2001 ,29(2):325～339.
28. Terskikh A V, Easterday M C, Li L, Hood L, Kornblum H I, Geschwind D H, Weissman I L. From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs[J]. Proc Natl Acad Sci USA , 2001, 98(14):7034-7939.
29. Chen Y N, Mickley L A, Schwartz A M, Acton E M, Hwang J L, Fojo A T. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein[J].J Biol Chem, 1990, 265(17): 10073-10080.
30. Doyle L A, Yang W ,Abruzzo L V, Krogmann T, Gao Y, Rishi A K, Ross D D. A multidrug resistance transporter from Human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci USA, 1998, 95(26): 15665-15670.
31. Krishnamurthy P, Schuetz J D. Role of ABCG2/BCRP in biology and medicine[J]. Annu Rev Pharmacol Toxicol, 2006,46:381-410.
32. Zhang W, Mojsilovic-Petrovic J, Andrade M F, Zhang H, Ball M, Stanimirovic D B. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels[J]. FASEB J, 2003, 17(14):2085 - 2087.
33. Robey R W, Honjo Y,Morisaki K, Nadjem T A, Runge S, Risbood M, Poruchynsky MS, Bates S E. Mutations at amin-oacid 482 in the ABCG2 gene affect substrate and antagonist specificity[J]. Br J Cancer, 2003,89(10):1971 - 1978.
34. Naylor C S, Jaworska E, Branson K, Embleton M J, Chopra R. Side population/ABCG2-positive cells represent a heterogeneous group of haemopoietic cells: Implications for the use of adult stem cells in transplantation and plasticity protocols[J]. Bone Marrow Transplant, 2005,35(4):353- 360.
35. Lechner A, Leech C A, Abraham E J, Nolan A L, Habeler J F. Nestin positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter [J]. Biochem Biophys Res Commun, 2002, 293: 670 - 674.
36. Wulf G G, Luo K L, Jackson K A, Brenner M K, Goodell M A. Cells of the hepaticside population contribute to liver regeneration and can be replenished with bone marrow stem cells[J]. Haematologica, 2003, 88(4):368- 378.
37. Summer R, Kotton D N, Sun X, Ma B, Fitzsimmons K, Fine A. Side population cells and Bcrp1 expression in lung[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 285(1):L97- 104.
1. SELL S. Stem cell origin of cancer and differentiation therapy [J]. Crit Rev Oncol Hematol,2004,51(1):1-28.
2. Hewitt H B.Studies of the dissemination and quantitative transplantation of alymphocytic leukemia of CBA in mice [J]. Br J Cancer 1958,12(3):378-401
3. Lapidot T,Sirard C,Vormoor J,Murdoch B,Hoang T,Caceres Cortes J,Minden M,Paterson B,Caligiuri M A,Dick J E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J].Nature,1994,367(6464):645-648.
4. Reya T, Morrison S J, Clarke M F, Weissman I L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414 (6859): 105 - 111.
5. Clarke M F,Morrison S J,Wicha M S. Isolation and use of solid tumor stem cells [M]. United States Patent Application, 2002, 20020119565.
6. Michael F, Clarke M F, John E. Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells[J]. Cancer Res, 2006, 66: 9339 - 9344.
7. Dick J E. Breast cancer stem cells revealed[J]. Proc Natl Acad Sci USA,2003, 100 (7) : 3547-3549.
8. Fialkow P J.Clonal origin of human tumors[J].Biochim Biophys Acta,1976,458 (3):283-321.
9. Pathak S. Organ- and tissue-specific stem cells and carcinogenesis[J].Anticancer Res,2002,22(3):1353-1356.
10. Keith W N. From stem cells to cancer: balancing immortality and neoplasia[J]. Oncogene, 2004, 23(29): 5092 - 5094.
11. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells[J]. Nature, 2003, 423 (6937): 255 -260.
12. Tsai RY. A molecular view of stem cell and cancer cell self - renewal[J]. Int J Biochem Cell Biol,2004, 36 (4): 684 - 694.
13. Lee J H,Schutte D,Wulf G,Fuzesi L,Radzun H J,Schweyer S,Engel W,Nayernia K. Stem cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl·XL pathway[J]. Hum Mol Genet, 2006, 15 (2): 201 - 211.
14. Krtolica A. Stem cell: balancing aging and cancer[J]. Int J Biochem Cell Biol, 2005, 37 (5): 935-941.
15. Yuspa S H,Morgan D L. Mouse skin cells resistant to terminal differentiation associated with initiation of carcinogenesis[J].Nature,1981,293(5827):72-74.
16. Bonnet D, Dick J E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med,1997, 3 (7) : 730 - 737.
17. Al Hajj M,Wicha M S,Benito Hemandez A,Morrison S J,Clarke M F.Prospective identification of tumorigenic breast cancer cells[J].Proc Natl Acad Sci USA,2003,100(7):3983-3988.
18. Sell S,Pierce G B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers[J].Lab Invest,1994,70(1):6-22.
19. Renan M J.How many mutations are required for tumorigenesis?Implications from human cancer data[J].Mol Carcinog,1993,7(3):139-146.
20. Potten C S,Hume W J,Reid P,Cairns J.The segregation of DNA in epithelial stem cells[J].Cell,1978,15(3):899-906.
21. Trosko J E,Chang C C.Stem cell of carcinogenesis[J].Toxicol Lett,1989,49 (2-3):283-295.
22. Li L, Neaves W B. Normal Stem Cells and Cancer Stem Cells: the niche matters[J]. Cancer Res,2006,66 (9): 4553 - 4557.
23. Yuan Y,Zhou L,Miyamoto T,Iwasaki H,Harakawa N,Hetherington C J,Burel S A,Lagasse E,Weissman I L,Akashi K,Zhang D E. AML1 - ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations [J]. Proc Natl Acad Sci USA,2001, 98 (18): 10398 - 10403.
24. Jamieson C H, Ailles L E, Dylla S J,Muijtjens M,Jones C,Zehnder J L,Gotlib J,Li K,Manz M G,Keating A,Sawyers C L,Weissman I L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML[J].N Engl J Med,2004,351(7): 657-667.
25. Kuo Y H,Landrette S F, Heilman S A, Perrat P N, Garrett L, Liu P P, Le Beau M M, Kogan S C, Castilla L H. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia[J]. Cancer Cell,2006, 9 (1): 57-68.
26. Blair A,Hogge D E,Sutherland H J.Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(+)/HLA-DR(-)[J]. Blood, 1998, 92(11):4325-4335.
27. Blair A, Hogge D E, Ailles L E, Lansdorp P M, Sutherland H J. Lack of expression of Thy-1 ( CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo[J ]. Blood,1997,89 (9) :3104-3112.
28. Blair A,Sutherland H J. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117) [J]. Exp Hematol,2000 ,28 (6):660-671.
29. Jordan C T, Upchurch D, Szilvassy S J, Guzman M L, Howard D S, Pettigrew A L, Meyerrose T, Rossi R, Grimes B, Rizzieri D A, Luger S M, Phillips G L. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells[J] .Leukemia,2000,14(10):1777-1784.
30. Guzman M L, Neering S J, Upchurch D, Grimes B, Howard D S, Rizzieri D A, Luger S M, Jordan C T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood, 2001,98 ( 8 ):2301-2307.
31. Guzman M L, Swiderski C F, Howard D S, Grimes B A, Rossi R M, Szilvassy S J, Jordan C T. Preferential induction of apoptosis for primary human leukemic stem cells[J ]. Proc Natl Acad Sci USA,2002, 99 (25):16220-16225.
32. Wang J C, Dick J E. Cancer stem cells: Lessons from leukemia[J]. Trends Cell Biol, 2005,15 (9): 494-501.
33. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti M A, Daidone M G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem /progenitor cell properties[J]. Cancer Res, 2005, 65(13): 5506-5511.
34. Ignatova T N, Kukekov V G, Laywell E D,Suslov O N,Vrionis F D, Steindler D A. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro[J]. Glia,2002,39(3):193-206.
35. Singh S K, Clarke I D, Terasaki M, Bonn V E, Hawkins C, Squire J, Dirks P B. Identification of a cancer stem cell in human brain tumors[J].Cancer Res, 2003,63(18):5821-5828.
36. Singh S K,Hawkins C, Clarke I D, Squire J A, Bayani J, Hide T, Henkelman R M,Cusimano M D,Dirks P B.Identification of human brain tumour initiating cells[J]. Nature,2004,432(7015):396-401.
37. Fomchenko E I,Holland E C.Stem cells and brain cancer[J].Exp Cell Res,2005,306(2): 323-329.
38. Hemmati H D, Nakano I, Lazareff J A, Masterman Smith M, Geschwind D H, Bronner Fraser M, Kornblum H I. Cancerous stem cells can arise f rom pediatric brain tumors [J] . Proc Natl Acad Sci USA, 2003,100 (25): 15178-15183.
39. Richardson G D, Robson C N, Lang S H, Neal D E, Maitland N J, Collins A T. CD133,a novel marker for human prostatic epithelial stem cells[J].J Cell Sci, 2004,117(16): 3539 - 3545.
40. Liu A Y,True L D,LaTray L,Ellis W J,Vessella R L,Lange P H,Higano C S,Hood L,van den Engh G. Analysis and sorting of prostate cancer cell types by flow cytometry[J]. Prostate,1999,40(3):192 - 199.
41. Collins A T, Berry P A, Hyde C, Stower M J, Maitland N J. Prospective identification of tumorigenic prostate cancer stem cells[J]. Cancer Res, 2005, 65(23)∶10946-10951.
42. Li C, Heidt D G, Dalerba P,Burant C F,Zhang L,Adsay V,Wicha M,Clarke M F,Simeone D M. Identification of pancreatic cancer stem cells[J]. Cancer Res, 2007, 67 (3):1030 -1037.
43. Seigel G M, Campbell L M,Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma[J]. Mol Vis,2005,11: 729 - 737.
44. Kim C F, Jackson E L, Woolfenden A E, Lawrence S, Babar I, Vogel S, Crowley D, Bronson R T, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer [J].Cell, 2005, 121 (6):823 - 835.
45. Fang D, Nguyen T K, Leishear K, Finko R, Kulp A N, Hotz S, Van Belle P A, Xu X, Elder D E, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas [J]. Cancer Res, 2005, 65 (20):9328 - 9337.
46. Gomella L G, Sargent E R, Wade T P, Anglard P, Linehan W M, Kasid A. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma [J]. Cancer Res, 1989, 49 (24 Pt 1): 6972-6975.
47. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus M C, Cantino D, Camussi G. Isolation of renal progenitor cells f rom adult human kidney [J]. Am J Pathol,2005,166 (2)∶545-555.
48. Forbes S, Vig P,Poulsom R,Thomas H, Alison M. Hepatic stem cells[J]. J Pathol, 2002,197(4):510-518.
49. Parent R, Marion M J, Furio L, Trepo C, Petit M A. Origin and characterization of a human bipotent liver progenitor cell line[J].Gastroenterology,2004,126(4): 1147-1156.
50. Hixson D C,Chapman L,McBride A,Faris R, Yang L.Antigenic phenotypes common to rat oval cells,primary hepatocellular carcinomas and developing bile ducts[J]. Carcinogenesis,1997,18(6):1169-1175.
51. Houghton J M, Stoicov C, Nomura S, Rogers A B, Carlson J, Li H, Cai X, Fox J G, Goldenring J R, Wang T C. Gastric cancer originating from bone Marrow-derived Cells [J]. Science,2004,306( 5701): 1568-1571.
52. O’Brien C A, Pollett A, Gallinger S,Dick J E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice [J]. Nature, 2007, 445 (7123): 106 - 110.
53. Ping Zhang,Hui Zuo,Takashi Ozaki,Nami Nakagomi,Kennichi Kakudo. Cancer stem cell hypothesis in thyroid cancer[J]. Pathology International, 2006, 56: 485 - 489.
54. Chan K S, Ailles L. Identification and characterization of cancer stem cells in bladder cancer[J]. Journal of Urology,2007, 177 (4): 257 - 257.
55. Goodell M A, Rosenzweig M, Kim H, Marks D F, DeMaria M, Paradis G, Grupp S A, Sieff C A, Mulligan R C, Johnson R P. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species[J]. Nat Med,1997,3(12):1337- 1345.
56. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in t he C6 glioma cell line[J]. Proc Natl Acad Sci USA, 2004,101 (3): 781 - 786.
57. Schinkel A H, Mayer U, Wagenaar E, Mol C A, van-Deemter L, Smit J J, van-der-Valk M A, Voordouw A C, Spits H, van-Tellingen O, Zi jlmans J M, Fibbe W E, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug- transporting) P- glycoproteins[J]. Proc Natl Acad Sci USA,1997,94(8): 4028- 4033.
58. Zhou S, Morris J J, Barnes Y, Lan L, Schuetz J D, Sorrentino B F. Bcrp1 geneexpression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J]. Proc Natl Acad Sci USA,2002,99(19):12339- 12344.
59. Zhou S, Schuetz J D, Bunting K D, Colapietro A M, Sampath J, Morris J J, Lagutina I, Grosveld G G, Osawa M, Nakauchi H, Sorrentino B P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype [J]. Nat Med, 2001, 7(9): 1028 - 1034.
60. Gussoni E, Soneoka Y,Strickland C D,Buzney E A,Khan M K,Flint A F,Kunkel L M,Mulligan R C. Dystrophin expression in the mdx mouse restored by stem cell transplantation[J]. Nature,1999, 401(6751):390- 394.
61. Falciatori I, Borsellino G, Haliassos N, Boitani C, Corallini S, Battistini L, Bernardi G, Stefanini M, Vicini E. Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis[J].FASEB J,2004,18(2): 376- 378.
1. Janes S M,Lowell S, Hutter C. Epidermal stem cells[J]. J Pathol, 2002,197(4): 479-491.
2. Lagasse E, Shizuru J A, Uchida N, Tsukamoto A, Weissman I L. Toward regenerative medicine[J]. Immunity,2001,14(4):425-436.
3. Perl A K,Wert S E,Nagy A,Lobe C G, Whitsett J A. Early restriction of peripheral and proximal cell lineages during formation of the lung[J]. Proc Natl Acad Sci USA,2002,99(16): 10482-10487.
4. Inayama Y, Hook G E, Brody AR, Jetten A M, Gray T, Mahler J, Nettesheim P. In vitro and in vivo growth and differentiation of clones of tracheal basal cells[J]. Am J Pathol,1989,134(3):539-549.
5. Ford J R, Terzaghi Howe M. Basal cells are the progenitors of primary tracheal epithelial cell cultures[J]. Exp Cell Res, 1992,198(1): 69-77.
6. Hong K U, Reynolds S D, Watkins S, Fuchs E, Stripp B R.In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent sub -populations[J]. Am J Physiol Lung Cell Mol Physiol,2004,286(4): L643-L649.
7. Borthwick D W, Shahbazian M, Krantz Q T,Dorin J R,Randell S H. Evidence for stem-cell niches in the tracheal epithelium[J].Am J Respir Cell Mol Biol,2001,24(6): 662-670.
8. Park K S, Wells J M,Zorn A M,Wer S E,Laubach V E,Fernandez L G,Whitsett J A. Transdifferentiation of ciliated cells during repair of the respiratory epithelium[J]. Am J Respir Cell Mol Biol, 2006,34(2): 151-157.
9. Reynolds S D, Giangreco A, Power J H, Stripp B R. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration[J]. Am J Pathol,2000,156 (1): 269-278.
10. Kim C F,J ackson E L,Woolfenden A E,Lawrence S,Babar I,Vogel S,Crowley D,Bronson R T,Jacks T.Identification of bronchioalveolar stem cells innormal lung and lung cancer[J]. Cell,2005,121(6): 823-835.
11. Kapanci Y, Weibel E R, Kaplan H P, Robinson F R. Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys.II Ultrastructural andmorphometric studies[J]. Lab Invest,1969,20(1): 101-118.
12. Evans M J,Cabral L J,Stephens R J,Freeman G. Renewal of alveolar epithelium in the rat following exposure to NO2[J]. Am J Pathol, 1973,70(2): 175-198.
13. Reddy R, Buckley S,Doerken M, Barsky L, Weinberg K,Anderson K D, Warburton D, Driscoll B. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells[J]. Am J Physiol Lung Cell Mol Physiol,2004,286(4): L658-L667.
14. Danto S I, Zabski S M, Crandall ED. Reactivity of alveolar epithelial cells in primary culture with type I cell monoclonal antibodies[J]. Am J Respir Cell Mol Biol,1992,6(3): 296-306.
15. Minguell J J,Erices A,Conget P.Mesenchymal stem cells[J]. Exp Biol Med,2001,226(12): 507-520.
16. Bruder S P,Jaiswal N, Haynesworth S E. Growth kinetics, self-renewal, and the osteogential potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation[J]. J Cell Biochem,1997, 64(2):278-294.
17. Prockop D J. Marrow stromal cells as stem cells for nonhematopoietic tissues[J]. Science,1997,276(5309): 71-74.
18. Krause D C,Theise N D,Collector M I,Henegariu O,Hwang S,Gardner R,Neutzel S,Sharkis S J. Multi-organ,multi-lineage engraftment by a single bone marrow-derived stem cell[J].Cell,2001,105(3): 369-377.
19. Albera C,Polak J M,Janes S,Griffiths M J,Alison M R,Wright N A,Navaratnarasah S,Poulsom R,Jeffery R,Fisher C,Burke M,Bishop A E. Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair[J]. Tissue Eng,2005,11(7-8) :1115-1121.
20. Kleeberger W, Versmold A, Rothamel T, Glockner S, Bredt M, Haverich A, Lehmann U,Kreipe H.Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury[J]. American Journal of Pathology,2003,162(5) : 1487-1494.
21. Sell S. Stem cell origin of cancer and differentiation therapy[J]. Crit Rev Oncol Hematol,2004,51 (1):1-28.
22. Burkert J,Wright N A,Alsion M R. Stem cells and cancer: an intimate relationship[J] . J Pathol,2006, 209 (3): 287 - 297.
23. Reya T,Morrison S J,Clarke M F,Weissman I L. Stem cells,cancer,and cancer stem cells[J]. Nature,2001,414(6859): 105 - 111.
24. Van der Kooy D, Weiss S. Why stem cells? [J]. Science,2000,287 (5457): 1439 - 1441.
25. Slack J M W. Stem cell in epithelial tissues[J]. Science,2000,287 (5457): 1431 - 1433.
26. Behbod F,Rosen J M. Will cancer stem cells provide new therapeutic targets? [J]. Carcinogenesis,2005,26 (4):703-711.
27. Berns A. Stem cells for lung cancer? [J]. Cell,2005,121 (6): 811-813.
28.黄盛东,刘晓红,白辰光.A549肺癌细胞株中肿瘤干细胞与克隆形成的关系[J].中华实验外科杂志,2006,23(9):1053-1055.
29. Robev R W,Honjo Y,van de Laar A,Miyake K,Regis J T,Litman T,Bates S E. A functional assay for detection of the mitoxantrone resistance protein,MXR (ABCG2) [J]. Biochim Biophys Acta. 2001,1512(2):171-182.
30. Ho M M,Ng A V,Lam S,Hung J Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J]. Cancer Res.2007,67(10): 4827-4833.